- Home
- FNGR vs CRBP Comparison
FNGR vs CRBP Comparison
Compare FNGR & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FNGR
- CRBP
- Stock Information
- Founded
- FNGR 2016
- CRBP 2009
- Country
- FNGR Singapore
- CRBP United States
- Employees
- FNGR N/A
- CRBP N/A
- Industry
- FNGR Computer Software: Prepackaged Software
- CRBP Biotechnology: Pharmaceutical Preparations
- Sector
- FNGR Technology
- CRBP Health Care
- Exchange
- FNGR Nasdaq
- CRBP Nasdaq
- Market Cap
- FNGR 72.0M
- CRBP 73.4M
- IPO Year
- FNGR N/A
- CRBP N/A
- Fundamental
- Price
- FNGR $1.45
- CRBP $5.52
- Analyst Decision
- FNGR
- CRBP Strong Buy
- Analyst Count
- FNGR 0
- CRBP 10
- Target Price
- FNGR N/A
- CRBP $60.89
- AVG Volume (30 Days)
- FNGR 282.2K
- CRBP 223.5K
- Earning Date
- FNGR 01-14-2025
- CRBP 03-11-2025
- Dividend Yield
- FNGR N/A
- CRBP N/A
- EPS Growth
- FNGR N/A
- CRBP N/A
- EPS
- FNGR N/A
- CRBP N/A
- Revenue
- FNGR $33,570,107.00
- CRBP N/A
- Revenue This Year
- FNGR $260.03
- CRBP N/A
- Revenue Next Year
- FNGR N/A
- CRBP $270.01
- P/E Ratio
- FNGR N/A
- CRBP N/A
- Revenue Growth
- FNGR N/A
- CRBP N/A
- 52 Week Low
- FNGR $1.03
- CRBP $5.49
- 52 Week High
- FNGR $3.96
- CRBP $61.90
- Technical
- Relative Strength Index (RSI)
- FNGR 52.62
- CRBP 29.17
- Support Level
- FNGR $1.55
- CRBP $5.76
- Resistance Level
- FNGR $1.83
- CRBP $6.17
- Average True Range (ATR)
- FNGR 0.14
- CRBP 0.40
- MACD
- FNGR 0.01
- CRBP 0.05
- Stochastic Oscillator
- FNGR 41.54
- CRBP 1.72
About FNGR FingerMotion Inc.
FingerMotion Inc is engaged in the provision of mobile payment and recharge services in the Chinese market. The company business line includes Telecommunications Products and Services; Value Added Products and Services; Short Message Services (SMS) and Multimedia Messaging Services (MMS); a Rich Communication Services (RCS) platform; Big Data Insights; and a Video Games Division (inactive). It principally earns revenue by providing mobile payment and recharge services to customers of telecommunications companies in China.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.